Login

Journal Front Page

News & Events

  • Call for article for January 2027 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 December, 2026 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • October 2026 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 15, Issue 4 (October 2026 Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

FORMULATION, DEVELOPMENT AND EVALUATION OF RIFAXIMIN LOADED SOLID LIPID NANOPARTICLES

Swapnil Uttam Dunedar*, Pruthviraj C. Meshram, Sachin B. Dudhe

Maharashtra Institute of Pharmacy, Betala, Bramhapuri, Dist. Chandrapur, Maharashtra

ABSTRACT

This research investigates the formulation, development, and evaluation of solid lipid nanoparticles (SLNs) loaded with rifaximin, an antibiotic known for its effectiveness against gastrointestinal infections. The primary objective was to enhance the bioavailability and therapeutic efficacy of rifaximin through the use of SLNs, which are designed to provide controlled release and improved stability. Various formulations were developed by varying lipid matrices and surfactants, and thorough characterization was performed to assess their physical and chemical properties. The characterization included measurement of particle size, entrapment efficiency, and drug content. The optimized formulation (F14) demonstrated a particle size of 215.45 nm and an impressive entrapment efficiency of 83.32%, indicating a successful incorporation of rifaximin within the lipid matrix. Additionally, the drug content was consistently high across formulations, further confirming the reliability of the preparation method. In vitro drug release studies were conducted to evaluate the cumulative release profile of rifaximin from the nanoparticles. The results indicated a sustained release characteristic, with 98.12% of the drug released over a period of 12 hours. This sustained release pattern aligns with zero-order kinetics, suggesting that the release rate of rifaximin from the SLNs is constant over time, which is beneficial for maintaining therapeutic levels of the drug in the systemic circulation. Overall, the findings of this study underscore the potential of rifaximin-loaded SLNs as an effective drug delivery system. The enhanced bioavailability and controlled release characteristics of the formulation could significantly improve patient compliance and therapeutic outcomes in managing gastrointestinal disorders.

Keywords: Rifaximin, Solid Lipid Nanoparticles, Drug Delivery, Bioavailability, Sustained Release, Formulation Development, Particle Size, Entrapment Efficiency, Kinetics.


[Full Text Article]